ARWR – Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.ARWR
$66.77Name : Arrowhead Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $9,231,456,256.00
EPSttm : -0.01
Arrowhead Pharmaceuticals, Inc.
$66.77
2.99%$2.06Float Short %
9.2
Margin Of Safety %
-50
Put/Call OI Ratio
0.34
EPS Next Q Diff
-0.9
EPS Last/This Y
-3.15
EPS This/Next Y
-1.34
Price
68.83
Target Price
57.73
Analyst Recom
1.71
Performance Q
138.25
Relative Volume
2.41
Beta
1.21
Ticker: ARWR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | ARWR | 39.85 | 0.25 | 0.23 | 25784 |
| 2025-11-11 | ARWR | 41.5 | 0.25 | 0.37 | 26993 |
| 2025-11-12 | ARWR | 41.44 | 0.25 | 0.30 | 27380 |
| 2025-11-13 | ARWR | 41.14 | 0.25 | 0.52 | 27646 |
| 2025-11-14 | ARWR | 41.26 | 0.25 | 0.56 | 27986 |
| 2025-11-17 | ARWR | 40.13 | 0.26 | 1.52 | 28516 |
| 2025-11-18 | ARWR | 40.51 | 0.31 | 0.17 | 30902 |
| 2025-11-19 | ARWR | 38.97 | 0.33 | 0.34 | 30257 |
| 2025-11-20 | ARWR | 38.1 | 0.34 | 0.16 | 30361 |
| 2025-11-21 | ARWR | 40.45 | 0.35 | 0.95 | 31734 |
| 2025-11-24 | ARWR | 44.25 | 0.29 | 0.10 | 24504 |
| 2025-11-25 | ARWR | 46.8 | 0.29 | 0.08 | 25342 |
| 2025-11-26 | ARWR | 57.32 | 0.27 | 0.35 | 26936 |
| 2025-12-01 | ARWR | 56.28 | 0.34 | 0.07 | 32351 |
| 2025-12-02 | ARWR | 58 | 0.33 | 0.02 | 32726 |
| 2025-12-03 | ARWR | 65.11 | 0.33 | 0.22 | 32896 |
| 2025-12-04 | ARWR | 64.7 | 0.32 | 0.16 | 35053 |
| 2025-12-05 | ARWR | 61.45 | 0.33 | 0.64 | 35415 |
| 2025-12-08 | ARWR | 68.58 | 0.34 | 0.28 | 35940 |
| 2025-12-09 | ARWR | 68.99 | 0.34 | 0.48 | 37562 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | ARWR | 39.85 | 72.5 | -96.7 | -0.22 |
| 2025-11-11 | ARWR | 41.50 | 72.5 | -101.5 | -0.22 |
| 2025-11-12 | ARWR | 41.43 | 72.5 | -93.5 | -0.22 |
| 2025-11-13 | ARWR | 41.13 | 72.5 | -92.5 | -0.22 |
| 2025-11-14 | ARWR | 41.25 | 85.1 | -94.3 | -0.22 |
| 2025-11-17 | ARWR | 40.15 | 85.1 | -88.7 | -0.22 |
| 2025-11-18 | ARWR | 40.47 | 85.1 | -100.5 | -0.22 |
| 2025-11-19 | ARWR | 38.97 | 85.1 | -91.8 | -0.22 |
| 2025-11-20 | ARWR | 38.09 | 85.1 | -89.5 | -0.22 |
| 2025-11-21 | ARWR | 40.44 | 88.5 | -105.3 | -0.22 |
| 2025-11-24 | ARWR | 44.23 | 88.5 | -111.3 | -0.22 |
| 2025-11-25 | ARWR | 46.79 | 88.5 | -104.5 | -0.22 |
| 2025-11-26 | ARWR | 57.73 | 88.5 | -136.9 | -0.22 |
| 2025-12-01 | ARWR | 56.26 | 57.2 | -322.1 | -3.33 |
| 2025-12-02 | ARWR | 57.95 | 57.2 | -315.2 | -3.33 |
| 2025-12-03 | ARWR | 65.07 | 57.2 | -332.1 | -3.33 |
| 2025-12-04 | ARWR | 64.68 | 93.1 | -308.6 | -3.16 |
| 2025-12-05 | ARWR | 61.44 | 93.1 | -300.8 | -3.16 |
| 2025-12-08 | ARWR | 68.60 | 93.1 | - | -3.16 |
| 2025-12-09 | ARWR | 68.83 | 93.1 | -310.3 | -3.16 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | ARWR | -0.60 | 0.93 | 9.07 |
| 2025-11-11 | ARWR | -0.60 | 0.93 | 9.07 |
| 2025-11-12 | ARWR | -0.60 | 0.93 | 9.18 |
| 2025-11-13 | ARWR | -0.60 | 0.93 | 9.18 |
| 2025-11-14 | ARWR | -0.60 | 0.93 | 9.12 |
| 2025-11-17 | ARWR | -0.66 | 2.64 | 9.12 |
| 2025-11-18 | ARWR | -0.66 | 2.64 | 9.12 |
| 2025-11-19 | ARWR | -0.66 | 2.64 | 9.12 |
| 2025-11-20 | ARWR | -0.66 | 2.64 | 9.12 |
| 2025-11-21 | ARWR | -0.66 | 2.64 | 9.12 |
| 2025-11-24 | ARWR | -0.66 | 5.39 | 9.19 |
| 2025-11-25 | ARWR | -0.60 | 5.39 | 9.19 |
| 2025-11-26 | ARWR | -0.60 | 5.39 | 9.04 |
| 2025-12-01 | ARWR | -0.61 | 5.63 | 9.21 |
| 2025-12-02 | ARWR | -0.69 | 5.63 | 9.21 |
| 2025-12-03 | ARWR | -0.69 | 5.63 | 9.21 |
| 2025-12-04 | ARWR | -0.69 | 5.63 | 9.21 |
| 2025-12-05 | ARWR | -0.69 | 5.63 | 9.20 |
| 2025-12-08 | ARWR | -0.69 | 5.58 | 9.20 |
| 2025-12-09 | ARWR | -0.69 | 5.58 | 9.20 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.18
Avg. EPS Est. Current Quarter
-0.1
Avg. EPS Est. Next Quarter
-1.08
Insider Transactions
-0.69
Institutional Transactions
5.58
Beta
1.21
Average Sales Estimate Current Quarter
244
Average Sales Estimate Next Quarter
58
Fair Value
34.54
Quality Score
46
Growth Score
37
Sentiment Score
91
Actual DrawDown %
26.5
Max Drawdown 5-Year %
-89
Target Price
57.73
P/E
Forward P/E
PEG
P/S
11.27
P/B
20.04
P/Free Cash Flow
59.58
EPS
-0.07
Average EPS Est. Cur. Y
-3.16
EPS Next Y. (Est.)
-4.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-0.2
Relative Volume
2.41
Return on Equity vs Sector %
-27.2
Return on Equity vs Industry %
-12.2
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
-0.27
EBIT Estimation
-310.3
Arrowhead Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 711
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Pasadena, California.
stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today
news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance
stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market
stock prices ARWR premarket after hours
ticker ARWR fair value insiders trading